If you’ve tried to hunt down concrete Wall Street forecasts or target prices for Trump Media & Technology Group (trading as DJT), you’ve probably noticed something weird: there are next to no official analyst predictions. This article unpacks why that is, walks you through the (lack of) available data, and shares real investor experiences and expert voices on the matter. I’ll also show you how to track what little public info there is, using screenshots and step-by-step guides. Along the way, we’ll look at the broader context—how analyst coverage works in the U.S. financial system, why certain stocks get skipped, and what this means for you if you’re trying to make sense of the hype around DJT.
Let’s get straight to the point: major Wall Street firms like Goldman Sachs, Morgan Stanley, or J.P. Morgan are not publishing target prices or “buy/hold/sell” ratings for Trump Media. I remember the first time I looked this up for a client who was curious about meme stocks—I thought, surely, someone must have issued a forecast after all that media attention. But no, nothing. Not even on Bloomberg Terminal or Refinitiv, which usually have at least one or two small-cap analysts making a guess. So what’s going on?
It turns out, this isn’t just a DJT thing. There’s a pattern when it comes to “SPAC” mergers, newly public companies, and especially those with heavy political baggage or meme stock status. Most major investment banks are wary of touching these names, either out of compliance caution (see SEC guidance on SPACs) or just to avoid controversy.
To double-check, I ran through the usual suspects: Yahoo Finance, Seeking Alpha, Bloomberg, and even paid research terminals. Every time, I hit a wall: “No analyst coverage available.” Here’s what that looks like in practice:
Here’s my real workflow, warts and all:
After a few hours, I’m starting to feel like the only “analysts” here are Reddit posters and Twitter threads. And that’s not a joke: the only forecasts you’ll find are from retail investors, bloggers, or meme-stock influencers, not from registered investment research analysts.
I reached out to two friends who work in equity research at bulge-bracket banks (I won’t name them for compliance reasons). Here’s what one told me, off the record:
“We have a compliance policy against covering stocks with ongoing legal disputes or where the company’s disclosures are still being audited. DJT falls into both camps, plus there’s the political risk. Even if we wanted to cover it, our legal team would be very cautious.”
This matches what the FINRA guidance on research coverage says: firms must ensure that their research is “fair, balanced, and not misleading,” and avoid conflicts of interest. For a high-profile, volatile, and politically charged stock like DJT, the risk of legal or reputational blowback is high. That’s why most firms are sitting this one out.
Even the SEC’s risk alert on SPACs highlights the need for extra caution in analyst coverage due to disclosure and structural risks.
It’s not just the U.S. where rules affect coverage. Different countries have their own standards for what counts as “verified” research and who can publish financial analysis. Here’s a quick comparison table:
Country | Standard/Regulation | Legal Basis | Enforcement Body |
---|---|---|---|
USA | FINRA Rule 2241 (Research Analyst and Research Report Rules) | Securities Exchange Act of 1934, Dodd-Frank | SEC, FINRA |
EU | MiFID II (Markets in Financial Instruments Directive II) | Directive 2014/65/EU | ESMA, National Regulators |
UK | FCA Conduct of Business Sourcebook (COBS 12) | Financial Services and Markets Act 2000 | FCA |
Japan | Financial Instruments and Exchange Act, Article 38 | Act No. 25 of 1948 | FSA |
What’s fascinating is that in the EU, MiFID II requires strict separation between research and sales. This makes it even harder for small-cap or controversial names to get covered, since analysts have to justify the cost of research. In practice, that means even less coverage for names like Trump Media outside the U.S.
Let’s imagine a scenario: Company X, the subject of a high-profile merger, wants to list on both the U.S. and German exchanges. In the U.S., analysts are wary due to regulatory and legal risks. In Germany, under BaFin’s rules, research coverage must meet strict independence and transparency standards. As a result, both markets see limited professional coverage—and retail investors are left relying on social media buzz.
Industry expert Dr. Lisa Müller, a compliance officer in Frankfurt, put it this way at a recent OECD roundtable (OECD Financial Markets Roundtable):
“For high-risk or controversial stocks, our compliance rules, as well as EU MiFID II, essentially force analysts to ‘sit out’ unless there is overwhelming market demand and clarity. This can create information vacuums that are quickly filled by less reliable sources.”
Without official analyst coverage, what should you do? Here’s what I tell friends and clients:
On a personal note, I once tried to “catch the bottom” on a meme stock with no analyst coverage. Let’s just say I learned the hard way: without professional analysis, you’re flying blind.
To wrap up: If you’re searching for Wall Street analyst targets or forecasts for Trump Media, you’re out of luck—at least for now. This is a product of regulatory caution, reputational risk, and the company’s unique profile. In the absence of official coverage, investors need to lean on primary filings, volatility tracking, and a healthy dose of skepticism.
My advice: Don’t mistake silence for a buy or sell signal. If you’re determined to invest, do your homework, and consider consulting with a licensed financial advisor who can help you interpret the raw data. And most of all, be aware that in the world of meme stocks, anything can happen.
For further reading, check out:
If Wall Street ever does start covering DJT, I’ll be the first to update this article with real targets and recommendations. Until then, stay smart and stay skeptical.